Cortice Biosciences, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 2014-01-01

Employees: -

Market Cap: -

Website: http://corticebiosciences.com

Clinical Trials

Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy

Phase 2

Terminated

Conditions: Glioblastoma Multiforme

Interventions: Drug: TPI 287
Drug: Bevacizumab

First Posted Date: 2014-01-28

Last Posted Date: 2018-01-31

Lead Sponsor: Cortice Biosciences, Inc.

Target Recruit Count: 17

Registration Number: NCT02047214

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
H Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, Florida, United States
🇺🇸
Washington University, School of Medicine, Saint Louis, Missouri, United States

and more 8 locations

Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma

Phase 1

Suspended

Conditions: Glioblastoma Multiforme

Interventions: Drug: TPI 287
Drug: Bevacizumab

First Posted Date: 2013-09-02

Last Posted Date: 2023-02-22

Lead Sponsor: Cortice Biosciences, Inc.

Target Recruit Count: 92

Registration Number: NCT01933815

Locations: 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 5 locations

A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer

Phase 2

Terminated

Conditions: Pancreatic Cancer

First Posted Date: 2007-11-06

Last Posted Date: 2014-01-22

Lead Sponsor: Cortice Biosciences, Inc.

Target Recruit Count: 23

Registration Number: NCT00553813

Locations: 🇪🇸
Hospital Madrid, Madrid, Spain
🇺🇸
Desert Hematology Oncology Medical Group, Inc., Rancho Mirage,, California, United States
🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States

and more 1 locations

A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: TPI 287

First Posted Date: 2007-05-28

Last Posted Date: 2014-01-22

Lead Sponsor: Cortice Biosciences, Inc.

Target Recruit Count: 26

Registration Number: NCT00479635

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸
University of Kentucky, Lexington, Kentucky, United States
🇺🇸
St. Barnabas Medical Center, Livingston, New Jersey, United States

and more 3 locations

Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Neoplasms
Hodgkin's Disease
Non-Hodgkin's Lymphoma

First Posted Date: 2005-11-21

Last Posted Date: 2007-10-15

Lead Sponsor: Cortice Biosciences, Inc.

Target Recruit Count: 45

Registration Number: NCT00256191

Locations: 🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States

Study of TPI 287 in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Neoplasms
Non-Hodgkin Lymphoma
Hodgkin Disease

First Posted Date: 2005-06-10

Last Posted Date: 2009-06-04

Lead Sponsor: Cortice Biosciences, Inc.

Target Recruit Count: 48

Registration Number: NCT00113724

Locations: 🇺🇸
Arizona Clinical Research Center, Tucson, Arizona, United States
🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸
Georgetown University Medical Center/Lombardi Cancer Center, Washington, DC, District of Columbia, United States

and more 1 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy